Determinants of adequate lymph node dissection following neoadjuvant chemotherapy in patients with urothelial muscle-invasive bladder cancer: results from the National Cancer Database.
Thomas F MonaghanViktor X FloresNicholas R SussDennis J RobinsMatthew T SmithBrian K McNeilLlewellyn M HyacintheJeffrey P WeissAndrew G WinerPublished in: International urology and nephrology (2020)
Established predictors of PLND may not necessarily be generalizable to all patients undergoing treatment for bladder cancer. The interplay between PLND and NAC merits further study, particularly in view of recent literature calling into question the survival benefit of PLND in patients pre-treated with NAC.
Keyphrases
- neoadjuvant chemotherapy
- muscle invasive bladder cancer
- patients undergoing
- lymph node
- end stage renal disease
- sentinel lymph node
- transcription factor
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- prostate cancer
- rectal cancer
- high grade
- radiation therapy
- early stage
- emergency department
- radical prostatectomy
- patient reported outcomes
- patient reported